
September 23, 2021
Therapy using dual immune system cells effectively controls neuroblastoma
Hongwei Du, PhD, Gianpietro Dotti, MD, and colleagues developed a new therapeutic approach that has shown successful results in lab models.
September 23, 2021
Hongwei Du, PhD, Gianpietro Dotti, MD, and colleagues developed a new therapeutic approach that has shown successful results in lab models.
April 23, 2021
Barbara Savoldo, MD, PhD, and Gianpietro Dotti, MD, have established a fund to develop a CAR-T therapy for glioblastoma in honor of Savoldo's sister, Sonia.
March 4, 2021
As part of a study led by Matthew Foster, MD, the advance was seen in a patient enrolled in a clinical trial using CAR-T to treat refractory acute B-cell leukemia.
January 25, 2021
The European Medicines Agency granted priority medicines designation to Tessa Therapeutics’ CD30 targeted CAR-T therapy for patients with relapsed or refractory Hodgkin lymphoma.
November 20, 2020
Clarivate’s 2020 Highly Cited Researchers list recognized 15 UNC Lineberger members for publishing some of the most influential scientific papers the past decade.
October 12, 2020
Zongchao Han, MD, PhD, Barbara Savoldo, MD, PhD, and colleagues report in Nature Cancer they used a combination of CAR-Ts and interleukin (IL)-15 to treat retinoblastoma in a mouse model.
December 20, 2018
At the 60th American Society of Hematology Annual Meeting in San Diego on Dec. 3, Eben Lichtman, MD, presented preliminary findings from preclinical studies of CAR T-cells directed towards a potential target called B7-H3, which is found on the cell surface of certain types of AML.
December 3, 2018
At the 60th American Society of Hematology Annual Meeting in San Diego on Monday, UNC Lineberger's Natalie Grover, MD, presented preliminary results from a clinical study of an investigational cellular immunotherapy for Hodgkin lymphoma and non-Hodgkin lymphoma expressing the CD30 protein marker.